Compare PRAX & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | TXG |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.5B |
| IPO Year | 2020 | 2019 |
| Metric | PRAX | TXG |
|---|---|---|
| Price | $254.33 | $70.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 19 |
| Target Price | ★ $650.00 | $77.00 |
| AVG Volume (30 Days) | 481.4K | ★ 3.8M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $245,893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $39,256.17 | $10.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 68.06 |
| 52 Week Low | $154.46 | $12.34 |
| 52 Week High | $392.70 | $102.81 |
| Indicator | PRAX | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 45.30 |
| Support Level | $237.78 | $56.98 |
| Resistance Level | $356.02 | $102.81 |
| Average True Range (ATR) | 12.32 | 7.54 |
| MACD | 2.23 | -1.56 |
| Stochastic Oscillator | 32.24 | 10.29 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).